USD 2.52
(2.02%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 57.41 Million USD | 3.13% |
2022 | 55.67 Million USD | -10.19% |
2021 | 61.99 Million USD | -1.42% |
2020 | 62.88 Million USD | -19.87% |
2019 | 78.47 Million USD | -9.64% |
2018 | 86.85 Million USD | 101.44% |
2017 | 43.11 Million USD | 9.46% |
2016 | 39.38 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 129.52 Million USD | 125.58% |
2024 Q2 | 117.6 Million USD | -9.2% |
2024 Q3 | 109.95 Million USD | -6.5% |
2023 Q3 | 59.44 Million USD | 4.31% |
2023 Q4 | 57.41 Million USD | -3.41% |
2023 FY | 57.41 Million USD | 3.13% |
2023 Q1 | 61.28 Million USD | 10.08% |
2023 Q2 | 56.99 Million USD | -7.0% |
2022 Q4 | 55.67 Million USD | 7.39% |
2022 Q3 | 51.84 Million USD | -7.93% |
2022 Q2 | 56.31 Million USD | -0.39% |
2022 FY | 55.67 Million USD | -10.19% |
2022 Q1 | 56.52 Million USD | -8.81% |
2021 Q4 | 61.99 Million USD | -5.05% |
2021 Q2 | 66.87 Million USD | 8.0% |
2021 Q3 | 65.29 Million USD | -2.37% |
2021 FY | 61.99 Million USD | -1.42% |
2021 Q1 | 61.92 Million USD | -1.53% |
2020 Q1 | 64.48 Million USD | -17.83% |
2020 FY | 62.88 Million USD | -19.87% |
2020 Q4 | 62.88 Million USD | 24.71% |
2020 Q3 | 50.42 Million USD | -20.65% |
2020 Q2 | 63.54 Million USD | -1.46% |
2019 Q4 | 78.47 Million USD | 60.76% |
2019 Q3 | 48.81 Million USD | -3.15% |
2019 Q2 | 50.4 Million USD | -25.85% |
2019 Q1 | 67.97 Million USD | -21.73% |
2019 FY | 78.47 Million USD | -9.64% |
2018 Q1 | 46.08 Million USD | 6.88% |
2018 FY | 86.85 Million USD | 101.44% |
2018 Q3 | 90.01 Million USD | 125.92% |
2018 Q4 | 86.85 Million USD | -3.51% |
2018 Q2 | 39.84 Million USD | -13.54% |
2017 FY | 43.11 Million USD | 9.46% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | 43.11 Million USD | 0.0% |
2016 FY | 39.38 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 94.978% |
Embecta Corp. | 1.21 Billion USD | 95.272% |
ANI Pharmaceuticals, Inc. | 904.42 Million USD | 93.651% |
Dynavax Technologies Corporation | 997.09 Million USD | 94.241% |
Esperion Therapeutics, Inc. | 205.79 Million USD | 72.1% |
Pacira BioSciences, Inc. | 1.57 Billion USD | 96.353% |
PainReform Ltd. | 9.93 Million USD | -478.228% |
Sunshine Biopharma, Inc. | 27.34 Million USD | -109.961% |
SCYNEXIS, Inc. | 128.41 Million USD | 55.286% |
China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -148.272% |
Cosmos Health Inc. | 66.29 Million USD | 13.391% |
Journey Medical Corporation | 76.84 Million USD | 25.285% |
Sunshine Biopharma, Inc. | 27.34 Million USD | -109.961% |
Safety Shot Inc | 12.7 Million USD | -351.784% |
Alpha Teknova, Inc. | 128.58 Million USD | 55.347% |
Intra-Cellular Therapies, Inc. | 728.29 Million USD | 92.116% |
Bright Green Corporation | 17.4 Million USD | -229.931% |
Procaps Group, S.A. | 460.18 Million USD | 87.523% |
Theratechnologies Inc. | 77.76 Million USD | 26.169% |
Harrow Health, Inc. | 311.75 Million USD | 81.582% |
Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -285.537% |
Biofrontera Inc. | 27.93 Million USD | -105.564% |
DURECT Corporation | 45.18 Million USD | -27.062% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 95.925% |
Cronos Group Inc. | 1.13 Billion USD | 94.938% |
OptiNose, Inc. | 107.72 Million USD | 46.701% |
Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 87.811% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2.626% |
RedHill Biopharma Ltd. | 23.04 Million USD | -149.133% |
Organogenesis Holdings Inc. | 460.02 Million USD | 87.519% |
Guardion Health Sciences, Inc. | 11.91 Million USD | -381.768% |
Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 29.786% |
Radius Health, Inc. | 1.71 Billion USD | 96.654% |
Universe Pharmaceuticals INC | 53.28 Million USD | -7.752% |
ProPhase Labs, Inc. | 91.92 Million USD | 37.54% |
Phibro Animal Health Corporation | 982.18 Million USD | 94.154% |
Procaps Group S.A. | 460.18 Million USD | 87.523% |
Alvotech | 950.09 Million USD | 93.957% |
TherapeuticsMD, Inc. | 43.3 Million USD | -32.578% |
Viatris Inc. | 47.68 Billion USD | 99.88% |
Rockwell Medical, Inc. | 52.17 Million USD | -10.053% |
Aytu BioPharma, Inc. | 118.09 Million USD | 51.38% |
SIGA Technologies, Inc. | 254.83 Million USD | 77.469% |
Tilray Brands, Inc. | 4.33 Billion USD | 98.676% |
Lifecore Biomedical, Inc. | 273.7 Million USD | 79.022% |
Shineco, Inc. | 84.17 Million USD | 31.791% |
PetIQ, Inc. | 868.22 Million USD | 93.387% |
Regencell Bioscience Holdings Limited | 8.43 Million USD | -580.452% |
Incannex Healthcare Limited | 17.04 Million USD | -236.822% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.234% |
Alimera Sciences, Inc. | 153.52 Million USD | 62.6% |
Silver Spike Investment Corp. | 88.57 Million USD | 35.177% |
Assertio Holdings, Inc. | 286.41 Million USD | 79.953% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -864.727% |
Petros Pharmaceuticals, Inc. | 33.79 Million USD | -69.897% |
Clever Leaves Holdings Inc. | 31.24 Million USD | -83.779% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -333.424% |
Avadel Pharmaceuticals plc | 261.12 Million USD | 78.011% |
Hempacco Co., Inc. | 18.04 Million USD | -218.227% |
Talphera, Inc. | 20.39 Million USD | -181.53% |
Alvotech | 950.09 Million USD | 93.957% |
Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 85.863% |
Lantheus Holdings, Inc. | 1.65 Billion USD | 96.523% |
Currenc Group, Inc. | 141.49 Million USD | 59.419% |
Kamada Ltd. | 351.96 Million USD | 83.687% |
Indivior PLC | 1.95 Billion USD | 97.057% |
Evoke Pharma, Inc. | 7.06 Million USD | -712.303% |
Flora Growth Corp. | 23.62 Million USD | -143.029% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -333.424% |
Evolus, Inc. | 188.99 Million USD | 69.62% |
HUTCHMED (China) Limited | 1.27 Billion USD | 95.513% |
Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 96.205% |
Akanda Corp. | 8.83 Million USD | -549.525% |